West Paces Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.04M | Sell |
8,090
-90
| -1% | -$19.4K | 0.34% | 40 |
|
|
2026
Q1 | $1.78M | Sell |
8,180
-853
| -9% | -$189K | 0.34% | 41 |
|
|
2025
Q4 | $2.06M | Sell |
9,033
-132
| -1% | -$30.1K | 0.4% | 37 |
|
|
2025
Q3 | $2.12M | Sell |
9,165
-52
| -0.6% | -$10.6K | 0.42% | 32 |
|
|
2025
Q2 | $1.71M | Buy |
9,217
+72
| +0.8% | +$13.4K | 0.36% | 37 |
|
|
2025
Q1 | $1.92M | Buy |
9,145
+110
| +1% | +$21.4K | 0.44% | 32 |
|
|
2024
Q4 | $1.61M | Sell |
9,035
-513
| -5% | -$94.3K | 0.39% | 36 |
|
|
2024
Q3 | $1.89M | Sell |
9,548
-244
| -2% | -$45.5K | 0.46% | 31 |
|
|
2024
Q2 | $1.68M | Sell |
9,792
-55
| -0.6% | -$9.11K | 0.44% | 36 |
|
|
2024
Q1 | $1.79M | Sell |
9,847
-306
| -3% | -$52.7K | 0.47% | 31 |
|
|
2023
Q4 | $1.57M | Buy |
10,153
+399
| +4% | +$58.2K | 0.44% | 31 |
|
|
2023
Q3 | $1.45M | Sell |
9,754
-24
| -0.2% | -$3.52K | 0.46% | 33 |
|
|
2023
Q2 | $1.32M | Buy |
9,778
+54
| +0.6% | +$7.92K | 0.39% | 37 |
|
|
2023
Q1 | $1.55M | Buy |
9,724
+250
| +3% | +$38.2K | 0.48% | 32 |
|
|
2022
Q4 | $1.53M | Sell |
9,474
-53
| -0.6% | -$8.13K | 0.49% | 31 |
|
|
2022
Q3 | $1.28M | Sell |
9,527
-36
| -0.4% | -$5.17K | 0.45% | 31 |
|
|
2022
Q2 | $1.46M | Buy |
9,563
+209
| +2% | +$31.9K | 0.5% | 32 |
|
|
2022
Q1 | $1.52M | Sell |
9,354
-420
| -4% | -$61K | 0.47% | 31 |
|
|
2021
Q4 | $1.32M | Buy |
9,774
+365
| +4% | +$43.1K | 0.41% | 37 |
|
|
2021
Q3 | $1.01M | Buy |
9,409
+7
| +0.1% | +$800 | 0.36% | 47 |
|
|
2021
Q2 | $1.06M | Sell |
9,402
-341
| -3% | -$38.4K | 0.39% | 42 |
|
|
2021
Q1 | $1.05M | Buy |
9,743
+507
| +5% | +$54.2K | 0.42% | 41 |
|
|
2020
Q4 | $990K | Buy |
9,236
+946
| +11% | +$90.9K | 0.44% | 40 |
|
|
2020
Q3 | $726K | Sell |
8,290
-41
| -0.5% | -$3.86K | 0.37% | 54 |
|
|
2020
Q2 | $818K | Buy |
8,331
+5,015
| +151% | +$442K | 0.44% | 43 |
|
|
2020
Q1 | $253K | Buy |
3,316
+1,979
| +148% | +$169K | 0.16% | 92 |
|
|
2019
Q4 | $118K | Buy |
1,337
+422
| +46% | +$35K | 0.06% | 129 |
|
|
2019
Q3 | $69.3K | Sell |
915
-1,943
| -68% | -$133K | 0.04% | 157 |
|
|
2019
Q2 | $208K | Sell |
2,858
-588
| -17% | -$46.2K | 0.13% | 101 |
|
|
2019
Q1 | $278K | Sell |
3,446
-7,860
| -70% | -$643K | 0.19% | 92 |
|
|
2018
Q4 | $1.04M | Sell |
11,306
-193
| -2% | -$17K | 0.8% | 31 |
|
|
2018
Q3 | $1.09M | Sell |
11,499
-453
| -4% | -$43K | 0.78% | 25 |
|
|
2018
Q2 | $1.11M | Buy |
11,952
+366
| +3% | +$35.7K | 0.83% | 22 |
|
|
2018
Q1 | $1.1M | Buy |
11,586
+441
| +4% | +$48.4K | 0.82% | 25 |
|
|
2017
Q4 | $1.08M | Buy |
11,145
+1,004
| +10% | +$94.6K | 0.8% | 23 |
|
|
2017
Q3 | $901K | Buy |
10,141
+1,160
| +13% | +$88.3K | 0.68% | 32 |
|
|
2017
Q2 | $651K | Buy |
8,981
+27
| +0.3% | +$1.81K | 0.52% | 44 |
|
|
2017
Q1 | $583K | Buy |
8,954
+1,031
| +13% | +$64.8K | 0.47% | 54 |
|
|
2016
Q4 | $496K | Buy |
+7,923
| New | +$484K | 0.46% | 55 |
|
Other funds holding ABBV
West Paces Advisors's ABBV Position: Q2 2026 in Review
West Paces Advisors reduced its AbbVie (ABBV) stake by 1.1% in Q2 2026, selling an estimated $19.4K and leaving 8,090 shares worth $2.04M. The position accounts for 0.34% of the portfolio, ranked #40.
West Paces Advisors first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. The position peaked at $2.12M in Q3 2025. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- West Paces Advisors held 8,090 shares of AbbVie worth $2.04M as of Q2 2026.
- West Paces Advisors sold 90 AbbVie shares in Q2 2026, an estimated $19.4K.
- AbbVie made up 0.34% of West Paces Advisors's portfolio in Q2 2026, its #40 holding.
- West Paces Advisors first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
- West Paces Advisors's AbbVie position peaked at $2.12M in Q3 2025.
- 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.